Personalized medicine – the idea of giving patients with treatments that are more effective and have fewer side effects – has been regarded as the greatest opportunity for the health-care system in recent years. In the meanwhile, for some therapies, this has already become a reality. However, because the necessary knowledge and technological foundation is still being developed, just a few applications, products, and services have been commercialized to date. Furthermore, current reimbursement practices, approval procedures, and medical professionals continue to favor traditional drugs. A large-scale implementation of personalized medicine necessitates a shift in the health-care system in general, as well as the pharmaceutical and life-science businesses in particular. While the economic importance of product innovations has long been recognized and encouraged, the focus over the last three decades has shifted to services and product-service systems.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States